Department of Psychiatry, Lucena Clinic Services, Dublin, Ireland
Department of Psychiatry, McMaster University, Hamilton, Ontario, Canada.
BMJ Open. 2024 Sep 12;14(9):e087632. doi: 10.1136/bmjopen-2024-087632.
Given the increasing rates of antipsychotic use in multiple psychiatric conditions, greater attention to the assessment, monitoring and documentation of their side effects is warranted. While a significant degree of attention has been provided to metabolic side effect monitoring, comparatively little is known about how clinicians screen for, document and monitor the motor side effects of antipsychotics (ie, parkinsonism, akathisia, dystonia and dyskinesias, collectively 'extrapyramidal side effects', EPS). This review aims to systematically assess the literature for insights into current trends in EPS monitoring practices within various mental health settings globally.
An electronic search will be performed using the OVID Medline, PubMed, Embase, CINAHL and APA PsycINFO databases for studies published in the last quarter century (1998 to present day). Two independent reviewers will conduct the initial title and abstract screenings, using predetermined criteria for inclusion and exclusion. A third reviewer will resolve disagreements if consensus cannot be reached. If selected for inclusion, full-text data extraction will then be conducted using a pilot-tested data extraction form. Quality assessment will be conducted for all included studies using a modified version of the Quality Improvement Minimum Quality Criteria Set. A narrative synthesis and summary of the data will be provided. All stages of the review process will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Ethical approval is not required. Findings will be peer reviewed, published and shared verbally, electronically and in print with interested clinicians and will also be presented as posters or talks at relevant medical conferences and meetings.
CRD42023482372.
鉴于在多种精神疾病中抗精神病药物的使用频率不断增加，有必要更加关注这些药物副作用的评估、监测和记录。虽然已经对代谢副作用监测给予了高度关注，但对于临床医生如何筛查、记录和监测抗精神病药物的运动副作用（即帕金森病、静坐不能、肌张力障碍和运动障碍，统称为“锥体外系副作用”，EPS），人们的了解相对较少。本综述旨在系统评估文献，以了解全球各种精神卫生环境中 EPS 监测实践的当前趋势。
将使用 OVID Medline、PubMed、Embase、CINAHL 和 APA PsycINFO 数据库进行电子检索，检索时间范围为过去四分之一个世纪（1998 年至今）。两位独立的审查员将使用预定的纳入和排除标准进行初步的标题和摘要筛选。如果无法达成共识，将由第三位审查员解决分歧。如果被选中纳入，将使用经过试点测试的数据提取表进行全文数据提取。将使用改良的质量改进最低质量标准集对所有纳入的研究进行质量评估。将提供数据的叙述性综合和总结。将按照系统评价和荟萃分析的首选报告项目报告审查过程的所有阶段。
不需要伦理批准。研究结果将经过同行评审，以书面、电子和印刷形式与感兴趣的临床医生分享，并将在相关医学会议和会议上以海报或演讲的形式展示。
PROSPERO 注册号：CRD42023482372。
